URGN

UroGen Pharma Ltd

Healthcare


Presented:03/06/2019
Price:$35.83
Cap:$0.71B
Current Price:$12.26
Cap:$0.52B

Presented

Date03/06/2019
Price$35.83
Market Cap$0.71B
Ent Value$0.60B
P/E RatioN/A
Book Value$5.56
Div Yield0%
Shares O/S19.76M
Ave Daily Vol217,470
Short IntN/A

Current

Price$12.26
Market Cap$0.52B
UroGen Pharma Ltd. is a clinical stage pharmaceutical company, which engages in the provision of non-surgical and localized solutions for urological pathologies to address a clinical unmet need in field of uro-oncology. Its pipeline includes upper tract urothelial carcinoma, low grade non muscle invasive bladder cancer, carcinoma in situ of the bladder, and overactive bladder. The company was founded by Asher Holzer in 2004 and is headquartered in Ra'anana, Israel.

Publicly traded companies mentioned herein: Allergan plc (AGN), Gilead Sciences Inc (GILD), Novartis AG (NVS), UroGen Pharma Ltd (URGN)

Highlights

With UroGen Pharma (URGN) stock at $36.50 (3/6/19 close), the presenter sees a favorable risk/reward setup and entry point. With a new CEO and rolling review underway for its lead therapy, UGN-101 (mitomycin gel), 2019 could be a transformative year for the company. UGN-101 could be the first drug ever approved to treat low-grade upper tract urothelial cancer (LG UTUC), and given the data published to-date, approval seems likely. Additionally, UGN-102 (Vesigel) is not far behind for low-grade non-muscle invasive bladder cancer (NMIBC), a much larger addressable market. If everything continues to play out in URGN’s favor, the presenter models upside to $66/share for an 80% gain.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Request access to DeMatteo Research for full access

Request Access

Already have an account?

Idea Discussion

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Idea Discussions display submitted commentary from our investor community.

To read and participate in the discussion with the presenter and investor base, request access to DeMatteo

Request Access

Already have an account?

An error occurred loading this content. Try again later or contact us.